Identification of immunotherapy early treatment failure in non-small cell lung cancer (NSCLC) using a novel cell-free DNA (cfDNA) tissue-agnostic genome-wide methylome enrichment assay.
Tuan Hoang(University Health Network), Adrian G. Sacher(University Health Network), Sally C. M. Lau(University Health Network), Yahan Yang(University Health Network), Brian Allen(Myriad Genetics), Lawson Eng(Princess Margaret Cancer Centre), Scott V. Bratman(University Health Network), Ben Brown, Anne‐Renee Hartman, Frances A. Shepherd(Princess Margaret Hospital), Justin Burgener, Collin Melton(Menlo School), Jing Zhang(Zhumadian Central Hospital), Geoffrey Liu(Princess Margaret Cancer Centre), Daniel D. De Carvalho(University Health Network), Penelope Ann Bradbury(University Health Network), Elena Elimova(University Health Network), Miguel García-Pardo(Hospital Universitario Ramón y Cajal), Abigail Williams, Natasha B. Leighl(Robarts Clinical Trials)
Cited by 1
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k